EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


LinkedIn facebook twitter youtube
News archive

 

CAR-T cell therapy is one of the most promising treatments in a number of types of cancer. In myeloma, very promising results were presented during the American Society of Hematology (ASH) Annual Meeting. Dr Mohamad Mohty, Head of Haematology and and celular therapy department, Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France, summarises for Myeloma Patients Europe (MPE) the most important CAR-T cells updates in myeloma at ASH.

 

 







Recent news

» COVID-19 vaccines for myeloma patients: what you need to know

» Horizon2020 CARAMBA Myeloma Pipeline information sheet now available in five languages

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.